Study on the clinical comprehensive evaluation of blood lipid-regulating drugs in five provinces and regions in Northwest China
- VernacularTitle:西北五省区调节血脂类药品临床综合评价研究
- Author:
Yuan QIAO
1
,
2
,
3
,
4
,
5
;
Hang ZHAO
1
,
2
,
3
,
4
,
5
;
Jiaxi DU
1
,
2
,
3
,
4
,
5
;
Jingyi MAN
1
,
2
,
3
,
4
,
5
;
Sen XU
1
,
2
,
3
,
4
,
5
;
Fangyi MA
1
,
2
,
3
,
4
,
5
;
Shuchen HU
1
,
2
,
3
,
4
,
5
;
Jin PENG
1
,
2
,
3
,
4
,
5
;
Minghuan JIANG
1
,
2
,
3
,
4
,
5
;
Mingyue ZHAO
1
,
2
,
3
,
4
,
5
;
Yu FANG
1
,
2
,
3
,
4
Author Information
1. Dept. of Pharmacy Administration and Clinical Pharmacy，School of Pharmacy，Xi’an Jiaotong University，Xi’an 710061，China
2. Institute of Drug Safety and Monitoring，Academy of Pharmaceutical Science and Technology，Western China Scientific and Technological Innovation Harbor，Xi’an 710061，China
3. Center for Drug Safety and Policy Research，Xi’an Jiaotong University，Xi’an 710061，China
4. Northwest Medicine Clinical Comprehensive Evaluation Center，Xi’an 710061，China
5. Northwest China Chapter，International Society for Pharmacoeconomics and Outcomes Research，Xi’an 710061，China
- Publication Type:Journal Article
- Keywords:
clinical comprehensive evaluation of drugs;
evaluation mechanism;
quality control;
index system;
rapid
- From:
China Pharmacy
2023;34(10):1165-1171
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore standardized evaluation process for clinical comprehensive evaluation of blood lipid- regulating drugs and perform rapid assessment of clinical comprehensive evaluation of blood lipid-regulating drugs with different mechanisms so as to provide reference for the drug catalogue selection and rational drug use of medical institutions. METHODS Referring to guidelines and consensus such as the guideline for the management of comprehensive clinical evaluation of drugs， the methods such as literature research， expert interviews， and Delphi expert consultation were used to establish a multi-dimensional and multi-criteria clinical comprehensive evaluation index system and quantitative scoring table for blood lipid-regulating drugs around the two main lines of technical evaluation and policy evaluation. Then 13 blood lipid-regulating drugs with different mechanisms in 21 third-grade class-A medical institutions from five provinces and regions of Northwest China were scored from both technical and policy dimensions to form a comprehensive evaluation result. RESULTS The clinical comprehensive evaluation index system and corresponding rapid evaluation quantitative scoring table were constructed for blood lipid-regulating drugs in the five northwest provinces and regions. The technicalevaluation section included 6 primary indicators， 13 secondary indicators， and 34 tertiary indicators， totaling 110 points. The policy evaluation section included 4 primary indicators and 6 secondary indicators， with a total score of 40 points （30 points for some drugs） and a total score of 150 points （or 140 points）. The scoring results showed that the highest score was atorvastatin， followed by rosuvastatin and simvastatin. CONCLUSIONS Statins are still the cornerstone of drug therapy for patients with dyslipidemia； the rapid evaluation quantitative scoring table constructed in this study is comprehensive， systematic and operable. The evaluation process in this study can provide empirical references for other groups to exploring the standardized path and quality control mechanism of clinical comprehensive evaluation of drugs.
